Argenx stock holds steady after 2025 revenue growth

Argenx stock (NL0010832176) remains tied to a larger commercial base after 2025 revenue reached EUR 2.13 billion, up 93% from EUR 1.10 billion in 2024, while product net sales rose to EUR 2.01 billion from EUR 1.02 billion a year earlier. The company also reported 2025 diluted earnings per share of EUR 1.74, versus a loss per share of EUR 1.54 in 2024.

Revenue up 93%

The 2025 top line matters because the jump was not a small base effect: product net sales accounted for nearly all revenue at EUR 2.01 billion, and the company described a broader global commercialization footprint in its investor materials. Those numbers give Argenx a very different earnings profile from the prior year.

For investors following the share, the key comparison is the 93% revenue increase and the swing from a 2024 loss per share of EUR 1.54 to 2025 EPS of EUR 1.74. That move shows how quickly the reported income statement improved over 12 months.

EPS turns positive

Argenx disclosed 2025 diluted EPS of EUR 1.74, a clear contrast with the EUR 1.54 loss per share in 2024. Net income also moved into positive territory at EUR 106 million in 2025, compared with a net loss of EUR 95 million in 2024.

Cash generation and scale are also visible in the filing: operating cash flow reached EUR 649 million in 2025, up from EUR 312 million in 2024, while cash, cash equivalents and current financial assets stood at EUR 2.47 billion at year-end 2025. That balance sheet gives the group room to keep funding development and commercial activity.

Investor focus on pipeline

The company’s lead product, Vyvgart, remains the main commercial driver, and the 2025 numbers show why the market tends to link Argenx stock to the uptake of that therapy. Argenx also continues to frame its story around a broader immunology pipeline, which investors typically read alongside the sales trend rather than in isolation.

The current investor-relations page at Argenx investor relations remains the company’s main source for report and presentation updates. That matters because the stock’s valuation still depends on how quickly commercial growth converts into durable profitability.

Vyvgart drives sales

Vyvgart is the representative product to watch because it sits at the center of Argenx’s reported revenue mix. The 2025 product sales figure of EUR 2.01 billion shows that the therapy has already become a large-scale commercial franchise rather than a launch-stage asset.

That scale is the reason the stock can react not only to clinical news but also to sales trajectory, cash flow, and margins. When one product carries most of the revenue base, even modest changes in adoption can matter more than broad sector moves.

Share level and market value

Without a live quote in the available material, the clearest market reference is the company’s reported year-end 2025 balance sheet and earnings base rather than a same-day trade. Argenx ended 2025 with EUR 2.47 billion in cash, cash equivalents and current financial assets, alongside EUR 106 million of net income.

That combination of EUR 2.47 billion in liquid resources and EUR 2.13 billion in 2025 revenue is the most concrete market-relevance anchor available here. It shows a company that entered 2026 with a stronger financial platform than it had a year earlier.